— Know what they know.
Not Investment Advice

CSBR NASDAQ

Champions Oncology, Inc.
1W: -3.4% 1M: +3.0% 3M: -20.6% YTD: -23.4% 1Y: -20.8% 3Y: -21.5% 5Y: -50.2%
$5.10
+0.00 (+0.09%)
 
Weekly Expected Move ±5.0%
$5 $5 $5 $5 $6
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 42 · $70.9M mcap · 5M float · 0.185% daily turnover · Short 21% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$70.9M
52W Range4.83-8.74
Volume10,083
Avg Volume9,591
Beta0.40
Dividend
Analyst Ratings
5 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEORobert Brainin
Employees214
SectorHealthcare
IndustryBiotechnology
IPO Date2007-02-02
One University Plaza
Hackensack, NJ 07601
US
201 808 8400
About Champions Oncology, Inc.

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

Recent Insider Trades

NameTypeSharesPriceDate
Breitfeld Philip P. A-Award 13,790 $6.80 2025-11-05
SIDRANSKY DAVID A-Award 21,216 $6.80 2025-11-05
Mendelson Daniel New A-Award 13,790 $6.80 2025-11-05
TOBIN SCOTT R A-Award 25,460 $6.80 2025-11-05
ACKERMAN JOEL A-Award 21,216 $6.80 2025-11-05

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms